Impact of Mutational Status on Clinical Response to Imetelstat in Patients with Lower-Risk Myelodysplastic Syndromes in the IMerge Phase 3 Study
Year: 2023
Type: conference-abstract
Source: Blood
Institutions: Azienda Ospedaliero-Universitaria Careggi, University of Florence, Yale Cancer Center, Yale University, Hôpital Saint-Louis, Université Paris Diderot, Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, University Hospital Leipzig
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4389243661
